Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma

Withdrawn before enrolling · Phase 1/Phase 2

Conditions studied: Recurrent Malignant Glioma

In brief

IL13-PE38QQR is an oncology drug product consisting of IL13 (interleukin-13) and PE38QQR (a bacteria toxin). IL3-PE38QQR is a protein that exhibits cell killing activity against a variety of IL13-receptor positive tumor cell lines indicating that it may show a therapeutic benefit. In reciprocal competition experiments, the interaction between IL13-PE38QQR and the IL13 receptors was shown to be highly specific for human glioma cells.

Key facts

Study ID

NCT00378235

Run by

INSYS Therapeutics Inc

People needed

0

Last updated by the study team

2014-11-13

Who can join

Age: 3 and older, up to 21. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of California San Francisco — San Francisco, California, United States
• Children's National Medical Center — Washington D.C., District of Columbia, United States
• Children's Memorial Hospital — Chicago, Illinois, United States
• Dana-Farber Cancer Institute-Dept of Pediatric Oncology — Boston, Massachusetts, United States
• Duke University Medical Center-Dept. of Pediatrics, Medicine & Surgery — Durham, North Carolina, United States
• The Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States
• Children's Hospital of Pittsburgh — Pittsburgh, Pennsylvania, United States
• St. Jude Children's Research Hospital — Memphis, Tennessee, United States
• Baylor College of Medicine-Dept of Pediatrics — Houston, Texas, United States
• Children's Hospital & Regional Medical Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.